DNA-based copy number analysis confirms genomic evolution of PDX models

Anna C.H. Hoge, Michal Getz, Anat Zimmer, Minjeong Ko, Linoy Raz, Rameen Beroukhim, Todd R. Golub, Gavin Ha, Uri Ben David

Research output: Contribution to journalArticlepeer-review

Abstract

Genomic evolution of patient-derived xenografts (PDXs) may lead to their gradual divergence away of their tumors of origin. We previously reported the genomic evolution of the copy number (CN) landscapes of PDXs during their engraftment and passaging1. However, whether PDX models are highly stable throughout passaging2, or can evolve CNAs rapidly1,3, remains controversial. Here, we reassess the genomic evolution of PDXs using DNA-based CN profiles. We find strong evidence for genomic evolution in the DNA-based PDX data: a median of ~10% of the genome is differentially altered between matched primary tumors (PTs) and PDXs across cohorts (range, 0% to 73% across all models). In 24% of the matched PT-PDX samples, over a quarter of the genome is differentially affected by CN alterations. Moreover, in matched analyses of PTs and their derived PDXs at multiple passages, later-passage PDXs are significantly less similar to their parental PTs than earlier-passage PDXs, indicative of genomic divergence. We conclude that PDX models indeed evolve throughout their derivation and propagation, and that the phenotypic consequences of this evolution ought to be assessed in order to determine its relevance to the proper application of these valuable cancer models.

Original languageEnglish
Article number30
Journalnpj Precision Oncology
Volume6
Issue number1
DOIs
StatePublished - Dec 2022

Fingerprint

Dive into the research topics of 'DNA-based copy number analysis confirms genomic evolution of PDX models'. Together they form a unique fingerprint.

Cite this